Saul J. Priceman

This paper demonstrates a personalized SNAP-TIL therapy platform that improves TIL efficacy by enriching them with neoantigen-reactive T-cells, achieving high CD3+ cell content and significant tumor growth inhibition in preclinical models.

Combining 177Lu-PSMA-617 radioligand therapy with PSCA-CAR T cells improves tumor control and survival in prostate cancer models by overcoming antigen heterogeneity and reshaping the immunosuppressive tumor microenvironment.

This study combines focal radiotherapy, cyclophosphamide, and PSCA-CAR T cells to enhance antitumor responses and survival in prostate cancer models.

This study develops and tests IL12-engineered human PSMA-CAR T cells for advanced prostate cancer, showing improved anti-tumor activity and safety.

The paper shows HDAC1 inhibition in MDSCs increases Malat1, decreases pSTAT3, induces apoptosis and cell cycle arrest, and reduces T cell suppression.

The paper develops a high-throughput platform to profile antigen-specific CD4+ T cells at single-cell resolution, identifying immunogenic features and functional heterogeneity in viral and cancer contexts.

This study engineers CAR T cells with PDL1-IL12 fusion proteins to enhance anti-tumor responses in solid tumors by improving T cell function and reducing systemic inflammation.

The paper identifies mitochondrial RNAs (mtRNAs) as chromatin-associated RNAs (caRNAs) that regulate nuclear transcription in response to stress and disease.